ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
Executive Summary
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
You may also be interested in...
ViiV Sees Cabenuva In Adolescents Addressing Adherence, Psychological Distress
Reducing the frequency of dosing to six times a year instead of daily pills could help reduce some of the psychological trauma teens with HIV face, chief medical officer Harmony Garges told Scrip.
ViiV Readies Entry To HIV PrEP Market After Apretude Approval
A long-acting injectable formulation of cabotegravir, Apretude could result in greater patient adherence to therapy, ViiV claims. The product will be priced at $3,700 per vial.
GSK Looks To Long-Acting Therapy To Restore Lead In HIV
GSK looks to Cabenuva to get ahead in the long-acting HIV therapy and PrEP market, but Gilead will not relinquish its lead easily.